Search Results - "Cupini, Samanta"

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Authors: Sammarco, Enrico Pellino, Antonio Bona, Eleonora et al.

Source: Cancers. Feb2026, Vol. 18 Issue 3, p409. 18p.

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.

Authors: Fanotto, Valentina Rossini, Daniele Casagrande, Mariaelena et al.

Source: Cancers. Nov2023, Vol. 15 Issue 22, p5451. 11p.

Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status.

Authors: Lessi, Francesca Morelli, Mariangela Franceschi, Sara et al.

Source: International Journal of Molecular Sciences. Jun2023, Vol. 24 Issue 12, p10147. 11p.

Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?

Authors: D'Erme, Angelo Massimiliano Fidanzi, Cristian Janowska, Agata et al.

Source: Dermatologic Therapy. Sep2021, Vol. 34 Issue 5, p1-3. 3p.

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.

Authors: Coltelli, Luigi Finale, Chiara Musettini, Gianna et al.

Source: Clinical & Experimental Medicine. Dec2023, Vol. 23 Issue 8, p5113-5120. 8p.

Immunotherapy‐induced eczema treated with dupilumab.

Authors: D'Erme, Angelo Massimiliano Fidanzi, Cristian Mori, Nicolò et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2024, Vol. 38 Issue 5, pe447-e449. 3p.

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.

Authors: Moretto, Roberto Rossini, Daniele Conca, Veronica et al.

Source: British Journal of Cancer. Sep2021, Vol. 125 Issue 6, p839-845. 7p.

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.

Authors: Antoniotti, Carlotta Marmorino, Federica Rossini, Daniele et al.

Source: European Journal of Cancer. Oct2025, Vol. 228, pN.PAG-N.PAG. 1p.

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.

Authors: Moretto, Roberto Rossini, Daniele Zucchelli, Gemma et al.

Source: European Journal of Cancer. Nov2020, Vol. 139, p81-89. 9p.

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

Authors: Fornaro, Lorenzo Baldi, Giacomo Giulio Masi, Gianluca et al.

Source: Critical Reviews in Oncology/Hematology. Jun2011, Vol. 78 Issue 3, p243-251. 9p.

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis.

Authors: Masi, Gianluca Vasile, Enrico Loupakis, Fotios et al.

Source: JNCI: Journal of the National Cancer Institute. Jan2011, Vol. 103 Issue 1, p21-30. 10p. 1 Diagram, 3 Charts, 3 Graphs.

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Authors: Masi, Gianluca Loupakis, Fotios Salvatore, Lisa et al.

Source: Lancet Oncology. Sep2010, Vol. 11 Issue 9, p845-852. 8p.

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.

Authors: Boccaccino, Alessandra Rossini, Daniele Raimondi, Alessandra et al.

Source: European Journal of Cancer. Aug2023, Vol. 189, pN.PAG-N.PAG. 1p.

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

Authors: Allegrini, Giacomo Di Paolo, Antonello Cerri, Elisa et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2006, Vol. 58 Issue 5, p585-593. 9p. 3 Charts, 1 Graph.

O-0027BEVACIZUMAB BEYOND PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING A FIRST-LINE TREATMENT CONTAINING BEVACIZUMAB: UPDATE OF BEBYP TRIAL BY GONO.

Authors: Salvatore, Lisa Masi, Gianluca Loupakis, Fotios et al.

Source: Annals of Oncology. Jun2013, Vol. 24 Issue suppl_4, piv22-iv22. 1p.

Mixed endometrial carcinoma: is it time to profile the two components separately?

Authors: Musettini G Pretelli P Giusti A et al.

Source: Frontiers in oncology [Front Oncol] 2026 Apr 23; Vol. 16, pp. 1735988. Date of Electronic Publication: 2026 Apr 23 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Authors: Coltelli L Orlandi P Finale C et al.

Source: Oncology research [Oncol Res] 2026 Apr 22; Vol. 34 (5), pp. 13. Date of Electronic Publication: 2026 Apr 22 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE

Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib.

Authors: Villanacci F Prost D Pieri F et al.

Source: The oncologist [Oncologist] 2025 Jul 04; Vol. 30 (7).

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Rebound Growth Following Temporary Discontinuation of BRAFi and MEKi in a Patient With Multifocal BRAFV600E-Mutant Primary Brain Tumor.

Authors: Pisano A Cupini S Santonocito OS et al.

Source: Neurology [Neurology] 2025 May 27; Vol. 104 (10), pp. e213621. Date of Electronic Publication: 2025 May 01.

Publication Type: Journal Article; Published Erratum

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE; PubMed not MEDLINE

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.

Authors: Dell'Aquila E Rossini D Galletti A et al.

Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2022 Sep; Vol. 21 (3), pp. 220-228. Date of Electronic Publication: 2022 Feb 19.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE